- Genomic Health, Inc’s (NASDAQ:GHDX) shares jumped 23.1% after it disclosed that the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, successfully defined the benefits of chemotherapy in early-stage breast cancer patients with Oncotype DX Breast Recurrence Score results of 11 to 25
- Shares of Bayer (DE:BAYGN) Aktiengesellschaft BAYN.DE declined 0.5% after the company announced that it will retire the name of Monsanto (NYSE:MON) after it finishes the $63 billion acquisition of the U.S. seed maker
- Nektar Therapeutics’ (NASDAQ:NKTR) shared plummeted 41.8% after mixed results came in from studies combining Nektar’s experimental drug NKTR-214 with Bristol-Myers Squibb's cancer immunotherapy
- Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) rose 47.9% after the company at the ASCO Annual Meeting reported updated interim Phase 1 clinical study results with DCC-2618
Genomic Health, Inc. (GHDX): Free Stock Analysis Report
Nektar Therapeutics (NKTR): Free Stock Analysis Report
Deciphera Pharmaceuticals, Inc. (DCPH): Free Stock Analysis Report
Original post
Zacks Investment Research